Novo Nordisk has announced that it's cutting the price of pre-filled insulin pens and vials by up to 75 percent for people living with diabetes starting in January 2024.
"We have been working to develop a sustainable path forward that balances patient affordability, market dynamics, and evolving policy changes," said Steve Albers, senior vice president of market access and public affairs at Novo Nordisk, Inc. "Novo Nordisk remains committed to ensuring patients living with diabetes can afford our insulins, a responsibility we take seriously."
Earlier this month, rival drugmaker Eli Lilly announced plans to reduce insulin prices by 70 percent and cap patient out-of-pocket costs for insulin at $35 per month.
The Biden administration has put public pressure on drugmakers to make medically necessary insulins more affordable. Novo Nordisk notably did not put a cap on out-of-pocket expenses.
Novo Nordisk will lower the price for four different brands, including NovoLog® and NovoLog® Mix 70/30 by 75 percent and Novolin® and Levemir® by 65 percent.
NBA champion Kendrick Perkins and Edly founder Chris Ricciardi discuss working together to create Nilly, a new platform where fans can invest in name, image, and likeness deals of their favorite college athletes.
Off the back of their latest earnings results, Hungryroot CEO Ben McKean discusses how the company is bringing healthy food straight to customers' doors and how it's using A.I.
Jack Ablin, Cresset Capital founding partner and CIO, breaks down the current market, from all eyes on Nvidia’s earnings to what sectors he’s seen deliver excellent returns.
Alberto Perlman, CEO of Zumba, shares what users can find on its new app, the demand for in-person fitness classes, and the secret to remaining a go-to exercise brand for decades.
Jamie Meyers, Senior Securities Analyst from Laffer Tengler Investments, discusses why he believes the rally will widen to small cap stocks and how the latest economic data is impacting his strategy.
